America Great Health disclosed preliminary results from a small, observational clinical study conducted at Zhejiang Kangjing Hospital involving ten subjects treated with ion-modified peptide products AX-3 and PPY-3 as adjunctive therapy for solid tumors, lymphoma, or bronchiectasis. The study observed symptom improvements in several patients but noted two deaths among those with advanced malignancies and multiple organ failure. The company emphasized the report's limitations, including the lack of a control group and concurrent standard cancer therapies, stating the data does not establish safety or efficacy. This filing provides early-stage research updates rather than definitive clinical trial outcomes. America Great Health operates in the biotechnology and healthcare sector, focusing on the development of ion-modified peptide products.